financetom
Business
financetom
/
Business
/
Beverage company Primo Brands Q2 sales miss estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Beverage company Primo Brands Q2 sales miss estimates
Aug 7, 2025 4:07 AM

Overview

* Primo Brands ( PRMB ) Q2 net sales rise 31.6% but miss analyst expectations

* Adjusted EPS for Q2 misses consensus, coming in at $0.36

* Company revises full-year 2025 guidance due to integration disruptions

* Primo Brands ( PRMB ) announces $250 mln share repurchase program

Outlook

* Primo Brands ( PRMB ) revises 2025 Net Sales, Adjusted EBITDA, Free Cash Flow guidance

* Company expects cost synergies of $200 mln in 2025, $300 mln in 2026

* Primo Brands ( PRMB ) anticipates service normalization by end of September

* Company announces $250 mln share repurchase program

Result Drivers

* MERGER IMPACT - Sales growth driven by merger with Primo Water, partially offset by facility sale in Ontario

* TORNADO DAMAGE - Hawkins facility tornado damage and integration service issues impacted Q2 results

* RETAIL EXPANSION - Continued expansion in retail distribution and strong demand for premium water products

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Miss $1.73 $1.81

bln bln (10

Analysts

)

Q2 Miss $0.36 $0.42

Adjusted (11

EPS Analysts

)

Q2 EPS $0.07

Q2 Miss $137.10 $158.90

Adjusted mln mln (8

Net Analysts

Income )

Q2 Miss $366.70 $421.50

Adjusted mln mln (10

EBITDA Analysts

)

Q2 EPS $0.08

from

Cont Ops

Q2 Net $30.50

Income mln

from

Cont Ops

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-alcoholic beverages peer group is "buy"

* Wall Street's median 12-month price target for Primo Brands Corp ( PRMB ) is $41.00, about 35.6% above its August 6 closing price of $26.41

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved